Abstract: In general, the disclosure is directed to bulk iron-nitride materials having a polycrystalline microstructure having pores including a plurality of crystallographic grains surrounded by grain boundaries, where at least one crystallographic grain includes an iron-nitride phase including any of a body centered cubic (bcc) structure, a body centered tetragonal (bct), and a martensite structure. The disclosure further describes techniques producing a bulk iron-nitride material having a polycrystalline microstructure, including: melting an iron source to obtain a molten iron source; fast belt casting the molten iron source to obtain a cast iron source; cooling and shaping the cast iron source to obtain a bulk iron-containing material having a body-centered cubic (bcc) structure; annealing the bulk iron-containing material at an austenite transformation temperature and subsequently cooling the bulk iron-containing material; and nitriding the bulk iron-containing material to obtain the bulk iron-nitride material.

Abstract: Disclosed herein are methods and systems for burning gaseous ammonia, including receiving a oxidizer gas into a chamber body such that the oxidizer gas generally flows in direction that extends along a longitudinal axis of the chamber body; introducing gaseous ammonia into the chamber body such that swirl is introduced into the gaseous ammonia; mixing the oxidizer gas and the gaseous ammonia to form a combustion mixture; igniting the combustion mixture; and combusting the combustion mixture for a duration such that the gaseous ammonia is converted to combustion products.

Abstract: Example artificial dental calculus models are described. In one example, an in vitro artificial dental calculus includes a dental substrate and a mineralized biofilm comprising an extracellular support material and at least one bacterial species. In one example, a method for creating an in vitro dental calculus model includes applying saliva to a dental substrate in a production environment, applying a mixture of an extracellular support material and at least one bacterial species to the dental substrate, applying a solution comprising calcium and phosphate to the mixture on the dental substrate, and removing the dental substrate from the production environment after a period of time during which a mineralized biofilm comprising the extracellular support material and the at least one bacterial species forms on the dental substrate.

Abstract: In some aspects, the present disclosure pertains to methods of treating a tissue volume comprising (a) administering an implantable composition comprising a releasable membrane-active agent to a target site such that the membrane-active agent is locally released to the tissue volume and (b) performing irreversible, reversible and/or thermal treatment by application of a pulsed electric field to the tissue volume. In other aspects, the present disclosure pertains to embolic compositions that comprise releasable membrane-active agents.

Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.

Abstract: The invention provides a compound of formula (I): or a salt thereof, wherein R1, R2, R3, B, X, and Y have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as TET inhibitors, epigenetic modulators, and for treating cancer, eating disorders, and as adjuvants in cancer immunotherapy.

Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.

Abstract: Provided herein are methods of manipulating ARID5B expression in immune cells such NK cells, T cells, and T cell and NK cell progenitors to enhance their persistence and function in vivo. Also provided herein are modified immune cells and compositions comprising such modified cells for anti-cancer, anti-viral, and other immunotherapies. In some embodiments, immune cells are genetically modified to increase ARID5B expression and, thus, improve persistence, increase in vivo anti-tumor efficacy, and increase viability and functionality of the modified cells after freezing and thawing.

Abstract: Certain embodiments of the invention provide conjugates, chemically self-assembled nanoring (CSAN), and cell modified with CSAN as described herein. Certain embodiments of the invention provide a method for cell-based drug delivery. Certain embodiments of the invention provide a method of transferring a cargo from a sender cell to a receiver cell as described herein.

Abstract: Self-supervised training of machine learning (“ML”) algorithms for reconstruction in inverse problems are described. These techniques do not require fully sampled training data. As an example, a physics-based ML reconstruction can be trained without requiring fully-sampled training data. In this way, such ML-based reconstruction algorithms can be trained on existing databases of undersampled images or in a scan-specific manner.

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

Abstract: A method for forming anodic aluminum oxide (AAO) on a substrate includes disposing an Al layer on the substrate, there being a Cu layer between the substrate and the Al layer, and a TiW alloy layer between and in contact with the Cu layer and the Al layer, anodizing the Al layer to provide an AAO layer comprising nanopores extending into the AAO layer to a barrier layer of the AAO at a base of each nanopore and converting at least some of the TiW alloy layer to TiW oxide, over-anodizing the barrier layer to remove at least a portion of the AAO of the barrier layer at the base of each nanopore, and exposing the AAO layer, the TiW oxide, and the TiW to a chemical etchant sufficient to extend the nanopores through the AAO layer to a surface of the Cu layer.

Abstract: The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.

Abstract: The systems and methods described herein include the use of Giant Plasma Membrane Vesicles (GPMVs) derived from cells expressing SPASM sensors (e.g., SPASM GPCR sensors). Herein provided are giant plasma membrane vesicle (GPMV) sensors containing a membrane-associated polypeptide, where the membrane-associated polypeptide contains a target G protein-coupled receptor (GPCR), a linker including an amino acid sequence flanked by a FRET donor and a FRET acceptor, and a receptor partner for the target GPCR, where the linker separates the target GPCR from the receptor partner. In another aspect, provided is a method for quantifying the intrinsic efficacy of a compound for a target GPCR. In another aspect, provided is a method for identifying a compound that interacts with a target GPCR.

Abstract: The present document relates to methods of forming an oxide material using van der Waals materials. Compositions and structures including such an oxide material are also described herein.

Abstract: A method is provided for operating an inverter of an inverter-based power resource providing electric power to a grid through one or more transformers. The method includes measuring voltages associated with terminals on a selected primary winding and/or measuring voltages associated with terminals on a selected secondary winding; and injecting currents into the primary terminals of the selected primary winding during a fault condition based on the measured voltages being indicative of the type of fault occurring. Preferably the inverter is operated to emulate at least some characteristics of fault currents provided by a generator having rotating magnets or electrical windings. An apparatus is configured to operate in accordance with the method and includes an electrical switching device circuit having input terminals for an inverter-based power resource and output terminals for providing AC electric power to an electric power grid. An inverter controller operates the electrical switching device circuit.

Abstract: Described herein is a method for producing a chimeric non-human animal expressing a human a MYF5, MYOD, MRF4 gene or a combination thereof gene comprising: a) generating an MYF5, MYOD, MRF4 or combination thereof null non-human animal cell, wherein both copies of the non-human MYF5, MYOD, MRF4 gene or combination thereof carry a mutation that prevents production of functional MYF5, MYOD, MRF4 protein or combination thereof in said non-human animal; b) creating a MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst by somatic cell nuclear transfer comprising fusing a nucleus from said MYF5, MYOD, MRF4 or combination thereof null non-human animal cell of a) into an enucleated non-human oocyte and activating said oocyte to divide so as to form an MYF5, MYOD, MRF4 or combination thereof null non-human blastocyst; c) introducing human stem cells into the MYF5, MYOD, MRF4 or combination null non-human blastocyst of b); and d) implanting said blastocyst from c) into a pseudopregnant surrogate non-human

Abstract: Techniques are described for automated microinjection of substances, such as genetic material, into microscopic objects, such as embryos. An example system includes a pressure controller, a stereoscopic imaging apparatus, a first camera, a second camera, and a computing system. The computing system is configured to apply one or more computer vision algorithms that determine, based on image data generated by the stereoscopic imaging apparatus, first camera, and second camera, a location of a tip of a micropipette and a location of a particular microscopic object in three-dimensional space. The computing system is further configured to control the pressure controller to cause the micropipette to eject the substance from the tip of the micropipette and into the particular microscopic object.

Abstract: The invention provides compounds of Formula I useful for the measurement of temperature by 19F magnetic resonance imaging.

Abstract: The invention is a new and distinct variety of male Populus tree named ‘NextGen’ that is characterized by its superior to above average field growth performance, its excellent to above average rooting rate, its disease resistance to foliar rusts (Melampsora sp.), leaf spots (Marssonina sp.) and stem cankers (Septoria sp.), its vigorous vegetative growth and production in nursery stoolbeds, its cold hardiness for overwintering and surviving in Minnesota with no frost damage, its wide-spread superior growth performance in many test locations (ie: MN, MI, WI, IA, IN, NY, etc); able to be considered “geo-robust” after years of testing, its replicated growth testing and evidence of promising performance and evaluation in phytoremediation research testing and applications, and its male flowers that do not produce seeds.